当前位置:循环首页>正文

[AHA2010]漫谈糖尿病肾病的治疗——Whaley-Connell教授专访

作者:  Whaley-Connell   日期:2010/11/26 16:02:06

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

<International Circulation>: The development of albuminuria has been identified as an additional possible risk marker that is almost unique to patients with chronic kidney disease, and a marker for predicting cardiovascular disease risk. Can treatment aimed at reducing albuminuria lead to cardiovascular risk reduction as well?

    <International Circulation>: The development of albuminuria has been identified as an additional possible risk marker that is almost unique to patients with chronic kidney disease, and a marker for predicting cardiovascular disease risk. Can treatment aimed at reducing albuminuria lead to cardiovascular risk reduction as well?

 《国际循环》:持续性蛋白尿已确定是慢性肾脏疾病患者特有的一个额外的可能风险标志物和心血管疾病的风险预测指标。旨在降低蛋白尿的治疗是否同样可以减少心血管疾病的风险?

    Prof. Whaley-Connell: We believe so. Most investigators currently believe that looking at albuminuria or proteinuria (albumin being the most predominant protein in circulating serum as well as filtered and lost in urine in those with kidney disease), is one of the most potent biomarkers that we have available today in looking at risk for kidney disease and cardiovascular disease progression. Most investigators now are looking at treatment strategies or interventions that target proteinuria specifically as a potential risk modifier.

    Dr Whaley-Connell: 我们认为可以。目前许多研究者认为,白蛋白尿或蛋白尿(白蛋白是体循环血清中最主要的蛋白,在肾脏疾病的患者体内,白蛋白可经肾脏过滤和尿液而丢失)是当今我们正在寻找的可用于预测肾脏疾病和心血管疾病进展的最有效的一个风险标志物。蛋白尿作为一个特殊的有效的风险修正因子,许多研究者目前正在寻找对其的治疗方案或干预手段。

[1]  [2]  [3]  [4]  下一页

版面编辑:沈会会  责任编辑:郭淑娟



糖尿病肾病Whaley-Connell

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530